Welcome!

News Feed Item

Lorus Therapeutics Announces Results of Annual and Special Meeting of Shareholders

TORONTO, ONTARIO -- (Marketwired) -- 03/27/14 -- Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Company") is pleased to announce that all of the nominees listed in the management proxy circular dated February 24, 2014 were elected as directors of Lorus at the Company's annual and special meeting of shareholders held today in Toronto (the "Meeting").

Each of the directors was elected by a majority of the votes cast by shareholders present at the Meeting or represented by proxy. The results of the vote are detailed below:

Nominee                                                              % Votes
                         Votes For    % Votes For Votes Withheld    Withheld
                                                                            
Dr. Denis Burger        26,516,223          99.90         27,125        0.10
                                                                            
Dr. William G. Rice     26,079,554          98.25        463,794        1.75
                                                                            
Dr. Bradley Thompson    25,978,864          97.87        564,484        2.13
                                                                            
Dr. Brian Underdown     26,075,592          98.24        467,756        1.76
                                                                            
Dr. Mark D. Vincent     25,977,168          97.87        566,180        2.13
                                                                            
Warren Whitehead        26,236,619          98.84        306,729        1.16
                                                                            
Dr. Jim A. Wright       26,413,818          99.51        129,530        0.49

At the Meeting, Lorus shareholders also voted to re-appoint KPMG LLP as auditor of the Company.

In addition, a special resolution approving certain amendments to the share option plan, the deferred share unit plan and the alternate compensation plan of the Corporation to remove the insider participation limits and remove the individual limit was approved by the required majority of shareholders present at the Meeting or represented by proxy.

Please refer to the Company's management proxy circular available on SEDAR at www.sedar.com for more details on the matters covered at the Meeting. Final voting results on all matters voted on at the Meeting will also be filed on SEDAR.

About Lorus

Lorus is a clinical stage biotechnology company with a commitment to discovering and developing targeted therapies addressing unmet medical needs in oncology. We aim to develop therapeutics focused on novel cellular targets on the leading edge of cancer research coupled to companion diagnostics to identify the optimal patient population for our products. Our pipeline of cancer drug candidates includes small molecule products and immunotherapies providing additive or synergistic efficacy without leading to overlapping toxicities with existing anti-cancer regimens, facilitating the adoption of doublet or possibly triplet therapies. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and US securities laws. Such statements include, but are not limited to, statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such risks and uncertainties could include, among others: our ability to continue to operate as a going concern; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. Such statements may not prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Contacts:
Enquiries:
Lorus Therapeutics Inc.
Greg Chow
Chief Financial Officer
416-798-1200
[email protected]

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Data center, on-premise, public-cloud, private-cloud, multi-cloud, hybrid-cloud, IoT, AI, edge, SaaS, PaaS... it's an availability, security, performance and integration nightmare even for the best of the best IT experts. Organizations realize the tremendous benefits of everything the digital transformation has to offer. Cloud adoption rates are increasing significantly, and IT budgets are morphing to follow suit. But distributing applications and infrastructure around increases risk, introdu...
At CloudEXPO Silicon Valley, June 24-26, 2019, Digital Transformation (DX) is a major focus with expanded DevOpsSUMMIT and FinTechEXPO programs within the DXWorldEXPO agenda. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term. A total of 88% of Fortune 500 companies from a generation ago are now out of business. Only 12% still survive. Similar percentages are found throug...
Atmosera delivers modern cloud services that maximize the advantages of cloud-based infrastructures. Offering private, hybrid, and public cloud solutions, Atmosera works closely with customers to engineer, deploy, and operate cloud architectures with advanced services that deliver strategic business outcomes. Atmosera's expertise simplifies the process of cloud transformation and our 20+ years of experience managing complex IT environments provides our customers with the confidence and trust tha...
Today's workforce is trading their cubicles and corporate desktops in favor of an any-location, any-device work style. And as digital natives make up more and more of the modern workforce, the appetite for user-friendly, cloud-based services grows. The center of work is shifting to the user and to the cloud. But managing a proliferation of SaaS, web, and mobile apps running on any number of clouds and devices is unwieldy and increases security risks. PJ Hough, Citrix Executive Vice President and...
Artifex Software began 25-years ago with Ghostscript, a page description language (PDL) interpreter software prevalent in printing and related applications requiring rendering and/or conversion from one software language to another. Founded by renowned computer scientist Dr. L. Peter Deutsch, our company has thrived on the basis of our sharp focus on this area of expertise, a zealous commitment to quality and a strong customer service orientation. Over 100 OEM partners representing some of th...
SUSE is a German-based, multinational, open-source software company that develops and sells Linux products to business customers. Founded in 1992, it was the first company to market Linux for the enterprise. Founded in 1992, SUSE is the world's first provider of an Enterprise Linux distribution.
Cloud-Native thinking and Serverless Computing are now the norm in financial services, manufacturing, telco, healthcare, transportation, energy, media, entertainment, retail and other consumer industries, as well as the public sector. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that pro...
ShieldX's CEO and Founder, Ratinder Ahuja, believes that traditional security solutions are not designed to be effective in the cloud. The role of Data Loss Prevention must evolve in order to combat the challenges of changing infrastructure associated with modernized cloud environments. Ratinder will call out the notion that security processes and controls must be equally dynamic and able to adapt for the cloud. Utilizing four key factors of automation, enterprises can remediate issues and impro...
Is your enterprise growing the right skills to fight the digital transformation (DX) battles? With 69% of enterprises describing the DX skill drought as being soft skills, rather than technology skills, are you ready to survive against disrupters? The next wave of business disruption is already crashing on your enterprise as AI, Blockchain and IoT change the nature and location of business. Now is the time to prepare. Drawing on experiences with large and midsize enterprises, Marco Coulter t...
Alan Hase is Vice President of Engineering and Chief Development Officer at Big Switch. Alan has more than 20 years of experience in the networking industry and leading global engineering teams which have delivered industry leading innovation in high end routing, security, fabric and wireless technologies. Alan joined Big Switch from Extreme Networks where he was responsible for product strategy for its secure campus switching, intelligent mobility and campus orchestration products. Prior to Ext...
In an age of borderless networks, security for the cloud and security for the corporate network can no longer be separated. Security teams are now presented with the challenge of monitoring and controlling access to these cloud environments, as they represent yet another frontier for cyber-attacks. Complete visibility has never been more important-or more difficult. Powered by AI, Darktrace's Enterprise Immune System technology is the only solution to offer real-time visibility and insight into ...
Atmosera delivers modern cloud services that maximize the advantages of cloud-based infrastructures. Offering private, hybrid, and public cloud solutions, Atmosera works closely with customers to engineer, deploy, and operate cloud architectures with advanced services that deliver strategic business outcomes. Atmosera's expertise simplifies the process of cloud transformation and our 20+ years of experience managing complex IT environments provides our customers with the confidence and trust tha...
FinTech is a disruptive innovation that denotes the adoption of technologies that have changed how traditional financial services work. While FinTech is now embedded deeply into the financial services ecosystem, the rise of digital age has paved way to FinTech 2.0 - which is rolling out innovative solutions through emerging technologies at a disruptive pace while maintaining the tenets of security and compliances. Blockchain as a technology has started seeing pilot adoption in FinTech around ...
Now is the time for a truly global DX event, to bring together the leading minds from the technology world in a conversation about Digital Transformation. DX encompasses the continuing technology revolution, and is addressing society's most important issues throughout the entire $78 trillion 21st-century global economy. DXWorldEXPO® has organized these issues along 10 tracks, 22 keynotes and general sessions, and a faculty of 222 of the world's top speakers.
Financial enterprises in New York City, London, Singapore, and other world financial capitals are embracing a new generation of smart, automated FinTech that eliminates many cumbersome, slow, and expensive intermediate processes from their businesses. Accordingly, attendees at the upcoming 23rd CloudEXPO, June 24-26, 2019 at Santa Clara Convention Center in Santa Clara, CA will find fresh new content in full new FinTech & Enterprise Blockchain track.